Continuing Allston Troubles Mean Another Brief Shutdown, Delay For Lumizyme Approval

An FDA "complete response" letter in relation to Genzyme's sBLA for Lumizyme says plant problems must be resolved before approval.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet